ArticleACS biomaterials science & engineering2023
Zeolites with Divalent Ions as Carriers in the Delivery of Epigallocatechin Gallate.
Article in ACS biomaterials science & engineering, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 12 citations in OpenAlex.
- Controlled EGCG Release from Zeolite-Coated Ti6Al4V: Effects of Divalent Ions on Release and Cytotoxicity.ACS biomaterials science & engineering · 2026Article
- Phenolics over Zeolites and Related Materials-Biomedical and Environmental Applications.Antioxidants (Basel, Switzerland) · 2024Review
- Advancements in wound healing: integrating biomolecules, drug delivery carriers, and targeted therapeutics for enhanced tissue repair.Archives of microbiology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epigallocatechin gallate (EGCG) is a compound with very high therapeutic potential in the treatment of osteoporosis and cancer. The disadvantages of this compound are its low stability and low bioavailability. Therefore, carriers for EGCG are sought to increase its use. In this work, new carriers are proposed, i.e., zeolites containing divalent ions of magnesium, calcium, strontium, and zinc in their structure. EGCG is retained on the carrier surface by strong interactions with divalent ions. Due to the presence of strong interactions, EGCG is released in a controlled manner from the carrier-ion-EGCG drug delivery system. The results obtained in this work confirm the effectiveness of the preparation of new carriers. EGCG is released from the carriers depending on the pH; hence, it can be used both in osteoporosis and in the treatment of cancer. The divalent ion used affects the sorption and release of the drug. The obtained results indicate the great potential of the proposed carriers and their advantage over the carriers described in the literature.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.